Pacira BioSciences, Inc. – NASDAQ:PCRX

Add to watchlist

$25.19

+5.54

+28.19%

Market closed

Open in about 15 hours

-9.70%

month

-9.70%

quarter

-42.73%

year

Market Cap	894.60M
Enterprise value	2.57B

P/E	122.53
EV/Sales	3.85
EV/EBITDA	18.31
Price/Sales	2.86
Price/Book	2.46
PEG ratio	-1.94
EPS	1.52

Revenue	681.75M
EBITDA	163.16M
Income	70.47M
Revenue Q/Q	4.22%
Revenue Y/Y	1.88%

Profit margin	2.39%
Oper. margin	10.64%
Gross margin	70.11%
EBIT margin	10.64%
EBITDA margin	23.93%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Pacira BioSciences Stock Forecast

M Q Y

Last Year

$12.67

Potential downside: -49.71%

Analysts Price target
Financials & Ratios estimates

Pacira BioSciences, Inc. (NASDAQ:PCRX): Profit margin
Jun 2023	169.46M	25.76M	15.2%
Sep 2023	163.92M	10.85M	6.62%
Dec 2023	181.24M	24.87M	13.72%
Mar 2024	167.11M	8.97M	5.37%

Pacira BioSciences, Inc. (NASDAQ:PCRX): Payout ratio
Payout ratio	0%

Pacira BioSciences, Inc. (NASDAQ:PCRX): Dividend Yield
2019	0.23%
2020	0.06%
2021	0.1%
2022
2023

Pacira BioSciences, Inc. (NASDAQ:PCRX): Debt to assets
Jun 2023	1542381000	734.40M	47.62%
Sep 2023	1534462000	702.91M	45.81%
Dec 2023	1574386000	704.25M	44.73%
Mar 2024	1583321000	691.15M	43.65%

Pacira BioSciences, Inc. (NASDAQ:PCRX): Cash Flow
Jun 2023	43.49M	7.32M	440K
Sep 2023	44.43M	-4.34M	-27.78M
Dec 2023	47.58M	8.37M	-1.77M
Mar 2024	49.10M	-15.53M	-2.81M

Pacira BioSciences alternative data

Pacira BioSciences, Inc. (NASDAQ:PCRX): Employee count
Aug 2023	715
Sep 2023	715
Oct 2023	715
Nov 2023	715
Dec 2023	715
Jan 2024	715
Feb 2024	715
Mar 2024	712
Apr 2024	712
May 2024	711
Jun 2024	711
Jul 2024	711

Pacira BioSciences
Hedge Funds Holdings Q2 2022

69.52% -30.48%

of PCRX is owned by hedge funds

192 -97

hedge funds hold PCRX stock

32.28M -16.83M

shares is hold by hedge funds

PCRX hedge funds holdings changes

Pacira BioSciences
Insider Trading

Pacira BioSciences, Inc. (NASDAQ:PCRX): Insider trades (number of shares)
Period	Buy	Sel
Mar 2024	0	119323
Jun 2024	0	18314
Jul 2024	0	2836
Aug 2024	17576	945
Sep 2024	0	500
Dec 2024	0	500

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	13 Dec 2024	GAUGLER DARYL officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	500	$19.76	$9,880
Sale	13 Sep 2024	GAUGLER DARYL officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	500	$12.86	$6,430
Purchase	16 Aug 2024	BIGAL MARCELO director director	Common Stock	1,512	$13.25	$20,034
Purchase	16 Aug 2024	BREGE LAURA director director	Common Stock	1,000	$12.81	$12,810
Purchase	14 Aug 2024	YANG MICHAEL J. director director	Common Stock	2,000	$12.9	$25,800
Purchase	12 Aug 2024	LEE FRANK D. director, officer..	Common Stock	8,264	$12.1	$99,994
Purchase	12 Aug 2024	FROIMSON MARK director director	Common Stock	1,400	$11.58	$16,212
Purchase	12 Aug 2024	BIGAL MARCELO director director	Common Stock	3,400	$12.01	$40,834
Sale	2 Aug 2024	SLONIN JONATHAN officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	945	$20.05	$18,947
Sale	2 Jul 2024	SLONIN JONATHAN officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	2,836	$28.25	$80,117

PCRX insider trading transactions

Pacira BioSciences
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 7 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 29 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 2 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

PCRX earnings call transcripts

Pacira BioSciences
Executives

Insider	Age	Compensation
Mr. David M. Stack (1950) Chairman & Chief Executive Officer	75	$1,590,000
Mr. Max Reinhardt (1971) Pres of Rest of World	54	$850,160
Ms. Kristen Williams (1974) Chief Admin. Officer & Sec.	51	$788,310
Mr. Charles A. Reinhart III, CPA, M.B.A. (1961) Chief Financial Officer	64	$702,360

Pacira BioSciences
Latest News

Friday, 20 December 2024
07:25	An Investigation Has Commenced on Behalf of Pacira BioSciences, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PCRX Losses.	accesswire.com
Thursday, 19 December 2024
07:25	Pacira BioSciences, Inc. (PCRX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates	accesswire.com
Wednesday, 18 December 2024
10:51	Here's Why Pacira (PCRX) is a Strong Momentum Stock	zacks.com
07:30	Levi & Korsinsky Reminds Shareholders of an Investigation into Pacira BioSciences, Inc. (PCRX) Regarding Potential Securities Fraud Allegations	accesswire.com
Tuesday, 17 December 2024
07:25	Lost Money on Pacira BioSciences, Inc.(PCRX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky	accesswire.com
Monday, 16 December 2024
07:15	Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacira BioSciences, Inc. (PCRX) Regarding Possible Securities Fraud Violations	accesswire.com
Friday, 13 December 2024
07:30	Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)	accesswire.com
Thursday, 12 December 2024
07:25	Pacira BioSciences, Inc. (PCRX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates	accesswire.com
Wednesday, 11 December 2024
08:05	DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.	prnewswire.com
07:25	Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX	accesswire.com
Tuesday, 10 December 2024
07:25	ATTENTION Pacira BioSciences, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights	accesswire.com
Monday, 9 December 2024
07:25	Levi & Korsinsky Announces an Investigation on Behalf of Pacira BioSciences, Inc. (PCRX) Shareholders Who May Have Been Affected by Fraud	accesswire.com
06:48	Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?	zacks.com
Friday, 6 December 2024
08:00	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	globenewswire.com
07:25	Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – PCRX	accesswire.com
Thursday, 5 December 2024
07:30	PCRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Pacira BioSciences, Inc. Investment	accesswire.com
Wednesday, 4 December 2024
13:11	PCRX Receives New Patent for Lead Pain Drug Exparel in the US	zacks.com
07:30	PCRX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Pacira BioSciences, Inc.	accesswire.com
Tuesday, 3 December 2024
07:30	Pacira Awarded New U.S. Patent Covering EXPAREL Composition	globenewswire.com
Friday, 29 November 2024
10:57	Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term	zacks.com
08:00	Pacira BioSciences, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PCRX	accesswire.com
Tuesday, 26 November 2024
07:30	ATTENTION Pacira BioSciences, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights	accesswire.com
Monday, 25 November 2024
13:25	Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses	seekingalpha.com
07:25	Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX	accesswire.com
Thursday, 21 November 2024
15:50	Levi & Korsinsky Announces an Investigation on Behalf of Pacira BioSciences, Inc. (PCRX) Shareholders Who May Have Been Affected by Fraud	accesswire.com
Thursday, 7 November 2024
11:10	Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth	zacks.com
Wednesday, 6 November 2024
20:09	Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:21	Pacira (PCRX) Q3 Earnings Beat Estimates	zacks.com
16:00	Pacira BioSciences Reports Third Quarter 2024 Financial Results	globenewswire.com
Wednesday, 30 October 2024
08:00	Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024	globenewswire.com

Ideas & Opinions

Seeking Alpha 23 May 2025

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Seeking Alpha 9 Apr 2025

Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Seeking Alpha 16 Mar 2023

BioXcel Therapeutics' Igalmi Commercial Launch: Not As Bad As Some May Think
Seeking Alpha 20 Oct 2022

Assessing Pacira BioSciences' Growth Prospects
Seeking Alpha 20 Sep 2022

Heron Therapeutics Is Not Out Of The Woods Yet
Seeking Alpha 11 Aug 2022

Pacira BioSciences: Pharmaceutical Near-Term Capital-Gain Prospect
Seeking Alpha 31 Mar 2022

Heron Therapeutics: Cash Is A Problem Again
Seeking Alpha 23 Oct 2021

Flexion Therapeutics: Bullish On The Buyout
Seeking Alpha 17 Sep 2021

Pacira BioSciences: Attractive Capital Gain Odds Next 3 Months
Seeking Alpha 21 May 2021

Heron Therapeutics: Zynrelef (Finally) Approved But With A Narrow Label

Frequently Asked Questions (FAQ)

What's the price of Pacira BioSciences stock today?

One share of Pacira BioSciences stock can currently be purchased for approximately $25.19.
When is Pacira BioSciences's next earnings date?

Unfortunately, Pacira BioSciences's (PCRX) next earnings date is currently unknown.
Does Pacira BioSciences pay dividends?

No, Pacira BioSciences does not pay dividends.
How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of 894.60M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1.22% to 674.98M US dollars.
What is Pacira BioSciences's stock symbol?

Pacira BioSciences, Inc. is traded on the NASDAQ under the ticker symbol "PCRX".
What is Pacira BioSciences's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Pacira BioSciences?

Shares of Pacira BioSciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Pacira BioSciences's key executives?
Pacira BioSciences's management team includes the following people:
- Mr. David M. Stack Chairman & Chief Executive Officer(age: 75, pay: $1,590,000)
- Mr. Max Reinhardt Pres of Rest of World(age: 54, pay: $850,160)
- Ms. Kristen Williams Chief Admin. Officer & Sec.(age: 51, pay: $788,310)
- Mr. Charles A. Reinhart III, CPA, M.B.A. Chief Financial Officer(age: 64, pay: $702,360)
How many employees does Pacira BioSciences have?

As Jul 2024, Pacira BioSciences employs 711 workers, which is 0% less then previous quarter.
When Pacira BioSciences went public?

Pacira BioSciences, Inc. is publicly traded company for more then 14 years since IPO on 3 Feb 2011.
What is Pacira BioSciences's official website?

The official website for Pacira BioSciences is pacira.com.
Where are Pacira BioSciences's headquarters?

Pacira BioSciences is headquartered at 5401 West Kennedy Boulevard, Tampa, FL.
How can i contact Pacira BioSciences?

Pacira BioSciences's mailing address is 5401 West Kennedy Boulevard, Tampa, FL and company can be reached via phone at +81 35536680.
What is Pacira BioSciences stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Pacira BioSciences in the last 12 months, the avarage price target is $12.67. The average price target represents a -49.71% change from the last price of $25.19.

Pacira BioSciences, Inc.

pacira.com

Exchange:

NASDAQ

Full time employees:

711

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

+81 35536680

5401 West Kennedy Boulevard
Tampa, FL 33609

CIK: 0001396814
ISIN: US6951271005
CUSIP: 695127100